CC-55 in Epilepsy and Neurodegeneration
CC-55 is a fully synthetic small molecule from the cyprolide class under lead optimisation. It is the first cyclophilin inhibitor that crosses the blood-brain barrier to a significant extent and serves as a tool compound to validate the involvement of cyclophilins in neurodegenerative diseases and epilepsy as suggested by a growing body of gene deletion or siRNA approaches. Cypralis believes that this chemical series will generate new drug candidates that will open new perspectives for the treatment of dementias, Parkinson’s disease, ALS, epilepsy and other neurological and/or neuroinflammatory disorders.
Please contact us to explore opportunities for collaboration or investment.